Skin cancer kills when malignant cells spread from the skin to vital organs, gradually destroying their ability to function. Globally, roughly 128,000 people die from skin cancer each year, split almost evenly between melanoma (about 58,700 deaths) and non-melanoma types (about 69,400 deaths). The specific way it becomes fatal depends on which organs the cancer reaches and how aggressively it grows.
How Melanoma Spreads to Vital Organs
Melanoma is the most dangerous form of skin cancer because of its tendency to metastasize early. Once it enters the bloodstream or lymphatic system, it can seed itself in the lungs, brain, liver, bones, and distant lymph nodes. The thicker the original tumor, the higher the risk. Melanomas thinner than 1 millimeter have a 30-year survival rate of about 95%. Once a tumor exceeds 4 millimeters in depth, that rate drops to roughly 54%, and the risk of dying from the cancer is 21 times higher than for the thinnest tumors.
When melanoma is still confined to the skin, the five-year survival rate is essentially 100%. Once it reaches nearby lymph nodes, survival drops to 76%. If it has spread to distant organs, the five-year survival rate falls to 34%. That steep decline reflects the damage cancer cells inflict once they take hold in places your body cannot afford to lose.
Lung Failure: The Leading Cause of Death
The most common cause of death in metastatic melanoma is lung metastases leading to respiratory failure. Cancer deposits in the lungs can block airways, fill lung tissue with tumor, or cause fluid to accumulate around the lungs (pleural effusion). As healthy lung tissue is replaced or compressed, the lungs progressively lose their ability to exchange oxygen and carbon dioxide. Breathing becomes increasingly difficult, and eventually the body can no longer maintain adequate oxygen levels.
Brain Metastases and Hemorrhage
Brain involvement is the second most common cause of melanoma-related death. Melanoma brain metastases are particularly dangerous because they have a strong tendency to bleed. Hemorrhage is found in most patients with melanoma that has spread to the brain. These bleeds can raise pressure inside the skull rapidly, damaging surrounding brain tissue.
Beyond hemorrhage, brain metastases can kill through several other pathways. Tumors can grow at the original site or seed new locations throughout the brain (distant brain failure). Cancer cells can also spread along the leptomeninges, the thin membranes surrounding the brain and spinal cord, cutting off the normal flow of cerebrospinal fluid and causing widespread neurological decline. Among patients who die from neurological causes, distant brain failure and hemorrhage each account for roughly 40% or more of those deaths, with leptomeningeal disease responsible for about 13-14%.
Liver Failure From Tumor Infiltration
When melanoma reaches the liver, cancer cells can infiltrate the tiny blood channels (sinusoids) that run through liver tissue. This infiltration obstructs blood flow, starves liver cells of oxygen, and causes them to die. In some cases, melanoma simply replaces so much liver tissue that the organ cannot perform its essential functions: filtering toxins, producing clotting factors, and regulating metabolism.
The progression can be rapid. Patients may develop decompensated liver failure, where the liver loses function faster than the body can compensate. This triggers a cascade of complications including fluid buildup in the abdomen, kidney failure (hepatorenal syndrome), and encephalopathy, a state of confusion and declining consciousness caused by toxins the liver can no longer clear. This cascade is often what ends a patient’s life.
How Non-Melanoma Skin Cancers Become Fatal
Squamous cell carcinoma is the non-melanoma type most likely to kill. It accounts for at least 20% of all skin cancer deaths worldwide. Only 1-4% of squamous cell carcinomas spread beyond the original site, but when they do, the outlook is serious. Nearly half of patients with metastatic squamous cell carcinoma have their spread detected within six months of the original diagnosis. If treatment fails to achieve a complete response, survival drops to zero within three years.
Certain tumors carry much higher risk. Squamous cell carcinomas on the lower lip are roughly 39 times more likely to metastasize than those in lower-risk locations. Tumors on the forehead, tumors larger than 2 centimeters, and tumors that invade deeply into underlying fat all significantly increase the chance of spread. When cancer reaches three or more lymph nodes, or extends beyond the lymph node capsule, the odds of a poor outcome increase by 8 to 10 times.
Basal cell carcinoma, the most common skin cancer, almost never metastasizes. In rare cases, it kills through relentless local invasion, growing into bone, nerves, or critical structures in the head and neck rather than spreading to distant organs.
Merkel Cell Carcinoma: A Rarer Threat
Merkel cell carcinoma is far less common than melanoma but more aggressive stage for stage. It tends to affect older adults and people with weakened immune systems. Survival rates are notably lower for men, for patients diagnosed at advanced stages, and for those who are immunosuppressed. Like melanoma, it spreads to lymph nodes and distant organs, where it can cause organ failure through similar mechanisms.
Why Advanced Skin Cancer Resists Treatment
Modern immunotherapy drugs have dramatically improved outcomes for some patients with advanced melanoma. But a significant number of patients do not respond, or they respond initially and then relapse. Some tumors lose the surface markers that the immune system uses to recognize and attack cancer cells. Others simply don’t have enough immune cells infiltrating the tumor for immunotherapy to amplify. Before immunotherapy became available, the median survival for metastatic melanoma was just 6-8 months. Current treatments have extended that to roughly 6-24 months depending on the approach, but for patients whose cancer resists treatment, the timeline to organ failure remains short.
The pattern of death in treatment-resistant cases follows the same organ-failure pathways: progressive lung disease, brain hemorrhage and swelling, or liver failure. What changes with effective treatment is simply whether those pathways are interrupted in time.
Thickness and Timing Shape the Risk
The single strongest predictor of whether a melanoma will eventually kill you is how deep the tumor has grown before it’s removed. A large Australian study tracking over 210,000 melanoma patients found that over 30 years, 7.1% of people with the thinnest melanomas (1 mm or less) died from their cancer. For tumors between 1 and 2 mm, that figure tripled to 21.6%. For tumors between 2 and 4 mm, it reached 34.2%. And for those thicker than 4 mm, 44.3% ultimately died from melanoma.
These numbers illustrate why early detection matters so much. A melanoma caught while still thin and confined to the upper layers of skin is almost universally survivable. The same cancer discovered after it has grown deep enough to access blood vessels and lymphatic channels becomes a systemic threat capable of shutting down the lungs, brain, or liver.